Although the MIPS and MACRA rule is preliminary and subject to change, CMS is clearly putting a lot of weight into it, and the act will be a major part of oncology practice.
Robert "Bo" Gamble
Advertisement
Articles by Robert "Bo" Gamble
Advertisement
Latest Updated Articles
Don't Get Caught Behind the MACRA CurveSeptember 22nd 2016
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
3
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
4
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
5